Evaluating dietary intervention before surgical treatment for epilepsy

ISRCTN ISRCTN41638605
DOI https://doi.org/10.1186/ISRCTN41638605
ClinicalTrials.gov number NCT02261753
Secondary identifying numbers 17696
Submission date
13/11/2014
Registration date
13/11/2014
Last edited
16/01/2020
Recruitment status
Stopped
Overall study status
Stopped
Condition category
Nervous System Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Focal cortical dysplasia (FCD) is an abnormality of brain development that is a common cause of epilepsy, which results in repeated seizures. The ketogenic diet is a high fat, low carbohydrate, low protein diet designed to mimic the effects of fasting. The aim of this study is to find out whether the ketogenic diet improves seizure control, brain development and quality of life in children with FCD type II who are about to undergo surgery for epilepsy.

Who can participate?
Children aged 5 - 15 with epilepsy that is resistant to drug treatment and believed to be the result of FCD type II, who are considered to be surgically treatable.

What does the study involve?
Participants are randomly allocated to either receive 6 months of treatment with a ketogenic diet before their surgery, or to proceed directly to surgery (no pretreatment).

What are the possible benefits and risks of participating?
Not provided at time of registration

Where is the study run from?
University of Liverpool (UK)

When is the study starting and how long is it expected to run for?
November 2014 to September 2019

Who is funding the study?
EU Seventh Framework Programme

Who is the main contact?
Dr Christiana Papamichael
c.papamichael@liverpool.ac.uk

Study website

Contact information

Dr Christiana Papamichael
Scientific

Department of Biostatistics
University of Liverpool
1st floor Duncan Building
Daulby Street
Liverpool
L69 3GA
United Kingdom

Email c.papamichael@liverpool.ac.uk

Study information

Study designRandomised; Interventional; Design type: Prevention
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Other
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleEvaluating Dietary Intervention Before surgicaL treatment for Epilepsy (EDIBLE)
Study acronymEDIBLE v1.0
Study objectivesThe investigators are undertaking the first European Randomised Controlled Trial (RCT) for epilepsy surgery in children with FCD type II, to prospectively evaluate the role of the KD prior to surgery in improving seizure outcome. The investigators will evaluate the role of the ketogenic diet as a disease-modifying treatment to achieve seizure control and improve neurodevelopment and quality of life. The ketogenic diet is a high fat, low carbohydrate, low protein diet designed to mimic the effects of fasting on the body. It will be administered by calculation as per local standardised classical ketogenic diet protocol with utilisation of long chain fat in a ratio of 2:1 to 4:1 carbohydrate and protein.
Ethics approval(s)14/LO/1885
Health condition(s) or problem(s) studiedTopic: Children; Subtopic: All Diagnoses; Disease: All Diseases
InterventionChildren will be randomised to either receive 6m treatment presurgery with a ketogenic diet, or to proceed direct to surgery (no pretreatment).
Intervention typeOther
Primary outcome measureTime to 6 month remission; the time to 6 months of seizure freedom from the date of randomisation
Secondary outcome measuresCurrent as of 19/09/2017:
1. Time to first seizure from date of randomisation;
2. Time to 12 month remission after randomisation;
3. Time to 24 month remission after randomisation (if enough time for follow-up is available);
4. Quality of life at 12 months after randomisation (and at 24 months if enough time for follow-up is available);
5. Adaptive behaviour assessment at 12 months (() after randomisation (and at 24 months if enough time for follow-up is available);
6. Methylation changes in tissue (DNA) from children pre-treated with the ketogenic diet. Tissue will be stored in the EEBB, and further distributed to DESIRE partners (Baker IDI Heart and Diabetes Institute Holdings Ltd, Varionostic GMBH,CEGAT) for further analysis;
7. Changes in peripheral DNA (blood platelets) following treatment with the KD. Tissue will be stored in the EEBB, and further distributed to DESIRE partners (Baker IDI Heart and Diabetes Institute Holdings Ltd, Varionostic GMBH,CEGAT) for further analysis;
8. Proportion of immediate AEs following resective surgery (i.e. surgical complications within 30 days) in the group pre-treated with KD compared to those without.
9. Compare the general AE occurrence between the group pre-treated with KD compared to the group without KD pre-treatment.

Previous secondary outcome meaures:
1. Methylation changes in tissue (DNA); Timepoint(s): At the time of surgery between ketogenic diet pre-treatment group vs non pre-treated group
2. Neuropsychological assessment; Timepoint(s): Neuropsychological assessment at 12 and at 24 months after randomisation
3. Peripheral DNA changes (blood); Timepoint(s): At baseline and at the time of surgery
4. Proportion of immediate AEs following resective surgery; Timepoint(s): Surgical complications within 30 days from surgery
5. Quality of life; Timepoint(s): Quality of life at 12 and at 24 months after randomisation
Overall study start date01/11/2014
Completion date26/07/2017
Reason abandoned (if study stopped)Participant recruitment issue

Eligibility

Participant type(s)Patient
Age groupChild
Lower age limit3 Years
Upper age limit15 Years
SexBoth
Target number of participantsPlanned Sample Size: 60; UK Sample Size: 60
Key inclusion criteriaCurrent as of 19/09/2017:
This is applicable to all participating countries with trial approvals working to Protocol V5.0 06/09/2016 except Austria and Germany (working to Protocol V2.0 17/03/2015)
1. Children aged 3 - 15 years;
2. MRI changes consistent with a diagnosis of FCD type II a or b;
3. History of at least two epileptic seizures in the past 6 months before randomisation;
4. Seizure semiology consistent with focal onset, agreed after pre-surgical discussion to be surgically treatable;
5. Parent/ legal representative willing to give consent.

Previous inclusion criteria:
1. Children aged 5-15 years
2. MRI changes consistent with a diagnosis of Focal Cortical Dysplasia type II a or b
3. History of continuing seizures for less than 5 years
4. History of at least two epileptic seizures in the past 6 months before randomisation
5. Seizure semiology consistent with focal onset, agreed after pre-surgical discussion to be surgically treatable
6. Failure of at least two antiepileptic drugs to control the seizures
7. Parent/legal representative willing to give consent
Key exclusion criteria1. Previous use of the ketogenic diet
2. Not a surgical candidate for Focal Cortical Dysplasia resection
3. Administration of the ketogenic diet is medically contraindicated
Date of first enrolment01/11/2014
Date of final enrolment26/07/2017

Locations

Countries of recruitment

  • Austria
  • Czech Republic
  • England
  • France
  • Germany
  • Italy
  • Scotland
  • Switzerland
  • United Kingdom
  • United States of America

Study participating centres

University of Liverpool
Liverpool
L69 3GA
United Kingdom
Krankenhaus Mara Maraweg
Bielefeld
33617
Germany
Bristol Royal Hospital for Children
24 Upper Maudlin Street
Bristol
BS2 8BJ
United Kingdom
Birmingham Children's Hospital
Steelhouse Lane
Birmingham
B4 6NH
United Kingdom
Royal Hospital for Sick Children
9 Sciennes Road
Edinburgh
EH9 1LF
United Kingdom
Children's Hospital Meyer
Viale Gaetano Pieraccini, 24
Florence
50139
Italy
Hôpitaux Universitaires de Genève
Rue Gabrielle-Perret-Gentil 4
Geneva
1205
Switzerland
Great Ormond Street Hospital for Children
Great Ormond Street
London
WC1N 3JH
United Kingdom
HFME - Hospices Civils De Lyon
3 Quai des Célestins
Lyon
69002
France
Royal Manchester Children's Hospital
Oxford Road
Manchester
M13 9WL
United Kingdom
Motol University Hospital
150 06, V Úvalu 84 Czechia
Prague
150 00
Czech Republic
Ospedale Pediatrico Bambino Gesù
Piazza di Sant'Onofrio, 4
Rome
00165
Italy
Hopital de Hautepierre
1 Avenue Molière
Strasbourg
67200
France
Schön Klinik Vogtareuth
Krankenhausstraße 20
Vogtareuth
83569
Germany
Medical University Vienna
Spitalgasse 23
Vienna
1090
Austria
Johns Hopkins Hospital
1800 Orleans Street
Baltimore
21287
United States of America

Sponsor information

University College London (UK)
University/education

67 Riding House Street
London
W1P 7PN
England
United Kingdom

ROR logo "ROR" https://ror.org/02jx3x895

Funders

Funder type

Government

Seventh Framework Programme
Government organisation / National government
Alternative name(s)
EC Seventh Framework Programme, European Commission Seventh Framework Programme, EU Seventh Framework Programme, European Union Seventh Framework Programme, FP7

Results and Publications

Intention to publish date26/07/2018
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planThe results from all the children will be analysed together and published as soon as possible in a peered reviewed scientific journal irrespective of findings. Participants and their parents or legal representative will be able to have collective findings disseminated to them in plain English by their neurologist or paediatrician. A lay summary will be made available on the trial website. Results will also be disseminated through conference presentations.
IPD sharing planNo individual data will be analysed. The identity of participants will remain confidential and results from blood and tissues samples donated for research purposes will not be copied into participants' medical notes.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
HRA research summary 28/06/2023 No No

Editorial Notes

16/01/2020: ClinicalTrials.gov number added.
19/09/2017: Study has been stopped due to recruitment issues. Recruitment end date has been updated from 30/09/2019 to 26/07/2017. Overall trial end date has been updated from 30/09/2019 to 26/07/2017.
12/02/2016: Plain English summary added.